Protalix BioTherapeutics (PLX) Non Operating Income (2012 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Non Operating Income of -$5000.0 for Q1 2026, down 101.21% year-over-year from $413000.0 in Q1 2025, and up 95.76% quarter-over-quarter from -$118000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Non Operating Income (2012 - 2026) Analysis & Trends
Protalix BioTherapeutics' Non Operating Income history runs 15 years deep, the most recent figure standing at -$5000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 101.21% year-over-year to -$5000.0; the TTM figure through Mar 2026 stood at -$526000.0 (down 199.81% YoY), while the FY2025 annual figure was -$108000.0, down 145.57% from the prior year.
- Non Operating Income for Q1 2026 stood at -$5000.0, up from -$118000.0 in the prior quarter.
- The five-year high for Non Operating Income was $413000.0 in Q1 2025, with the low at -$811000.0 in Q4 2023.
- The 5-year median for Non Operating Income is -$118000.0 (2025), against an average of -$185470.6.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income tumbled 507.37% in 2023, then surged 235.77% in 2025.
- Protalix BioTherapeutics' Non Operating Income stood at -$715000.0 in 2022, then dropped by 13.43% to -$811000.0 in 2023, then surged by 113.19% to $107000.0 in 2024, then plunged by 210.28% to -$118000.0 in 2025, then surged by 95.76% to -$5000.0 in 2026.
- Business Quant data shows PLX's Non Operating Income at -$5000.0 in Q1 2026, -$118000.0 in Q4 2025, and $108000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 188,000.00 |
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | -118,000.00 |
| Sep 30, 2025 | 108,000.00 |
| Jun 30, 2025 | -511,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | -148,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Dec 31, 2023 | -811,000.00 |
| Sep 30, 2023 | 168,000.00 |
| Jun 30, 2023 | -774,000.00 |
| Mar 31, 2023 | -477,000.00 |
| Dec 31, 2022 | -715,000.00 |
| Sep 30, 2022 | -442,000.00 |
| Jun 30, 2022 | 190,000.00 |
| Mar 31, 2022 | -416,000.00 |
| Dec 31, 2021 | -910,000.00 |
| Sep 30, 2021 | -2.31 Mn |